These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 3909329)

  • 41. Safety of aztreonam and SQ 26,992 in elderly patients with renal insufficiency.
    Sattler FR; Schramm M; Swabb EA
    Rev Infect Dis; 1985; 7 Suppl 4():S622-7. PubMed ID: 4081474
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Pharmacokinetics and clinical studies on aztreonam in neonates and premature infants (the first report). Study on effectiveness and safety in mono-therapy with aztreonam. A study of aztreonam in the Perinatal Co-research Group].
    Fuji R; Hashira S; Tajima T; Meguro H; Abe T; Sakata H; Kakehashi H; Fujita K; Murono K; Kaeriyama M
    Jpn J Antibiot; 1990 Mar; 43(3):543-62. PubMed ID: 2197468
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Suboptimal aminoglycoside dosing in critically ill patients.
    Rea RS; Capitano B; Bies R; Bigos KL; Smith R; Lee H
    Ther Drug Monit; 2008 Dec; 30(6):674-81. PubMed ID: 19057371
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics and plasma bactericidal activity of aztreonam in low-birth-weight infants.
    Likitnukul S; McCracken GH; Threlkeld N; Darabi A; Olsen K
    Antimicrob Agents Chemother; 1987 Jan; 31(1):81-3. PubMed ID: 3105443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aztreonam in treatment of intra-abdominal infections.
    Malangoni MA
    Urology; 1988 Jun; 31(6 Suppl):28-32. PubMed ID: 3287747
    [TBL] [Abstract][Full Text] [Related]  

  • 46. How and why aztreonam works.
    Rittenbury MS
    Surg Gynecol Obstet; 1990; 171 Suppl():19-23. PubMed ID: 2244291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Basic and clinical trials of aztreonam in the field of pediatrics].
    Motohiro T; Kawakami A; Tanaka K; Koga T; Shimada Y; Tomita N; Sakata Y; Fujimoto T; Nishiyama T; Tominaga K
    Jpn J Antibiot; 1985 Nov; 38(11):3358-77. PubMed ID: 3912525
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Clinical and pharmacokinetic evaluation of aztreonam in neonates].
    Sakata H; Kakehashi H; Fujita K; Murono K; Kaeriyama M; Oka T; Yoshioka H; Hiramoto A; Mori Y; Maruyama S
    Jpn J Antibiot; 1990 Mar; 43(3):388-95. PubMed ID: 2374291
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Single-dose pharmacokinetics of aztreonam in healthy volunteers and renal failure patients.
    el Guinaidy MA; Nawishy S; Abd el Bary M; Sabbour MS
    J Chemother; 1989 Jun; 1(3):164-9. PubMed ID: 2795125
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aztreonam therapy for serious gram-negative infections in children.
    Stutman HR; Chartrand SA; Tolentino T; Friedhoff L; Marks MI
    Am J Dis Child; 1986 Nov; 140(11):1147-51. PubMed ID: 3766490
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The pharmacokinetics of aztreonam and penetration into the bronchial secretions of critically ill patients.
    Boccazzi A; Langer M; Mandelli M; Ranzi AM; Urso R
    J Antimicrob Chemother; 1989 Mar; 23(3):401-7. PubMed ID: 2732121
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of low-dose aztreonam in the treatment of moderate to severe infections due to gram-negative bacilli.
    Clergeot A; Steru D; Rosset MA; Carbon C
    Rev Infect Dis; 1991; 13 Suppl 7():S648-51. PubMed ID: 2068476
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Aztreonam: the first monobactam antibiotic.
    Stutman HR
    Pediatr Infect Dis J; 1987 Jun; 6(6):550-5. PubMed ID: 3302907
    [No Abstract]   [Full Text] [Related]  

  • 55. Efficacy and safety of aztreonam versus tobramycin for aerobic gram-negative bacilli lower respiratory tract infections.
    Rodriguez JR; Ramirez-Ronda CH
    Am J Med; 1985 Feb; 78(2A):42-3. PubMed ID: 4038578
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?
    Udy AA; Lipman J; Jarrett P; Klein K; Wallis SC; Patel K; Kirkpatrick CM; Kruger PS; Paterson DL; Roberts MS; Roberts JA
    Crit Care; 2015 Jan; 19(1):28. PubMed ID: 25632974
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
    Naber KG; Dette GA; Kees F; Knothe H; Grobecker H
    J Antimicrob Chemother; 1986 Apr; 17(4):517-27. PubMed ID: 3710959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis.
    Kildoo CW; Harralson AF; Folli HL; Kelly PC; Nussbaum E
    Drug Intell Clin Pharm; 1987; 21(7-8):639-42. PubMed ID: 3608813
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aztreonam (Azactam).
    Med Lett Drugs Ther; 1987 May; 29(739):45-7. PubMed ID: 3553881
    [No Abstract]   [Full Text] [Related]  

  • 60. Controlled trial of aztreonam vs. tobramycin and azlocillin for acute pulmonary exacerbations of cystic fibrosis.
    Bosso JA; Black PG
    Pediatr Infect Dis J; 1988 Mar; 7(3):171-6. PubMed ID: 3128767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.